Business
‘We’re not in business to lose money’: Q&A with Sensi Brands CEO Tony Giorgi
When massive amounts of capital were being poured into greenhouse construction a few years ago during the heyday of Canada’s cannabis stock mania, the chief executive of Toronto-based Sensi Brands made a decision.
CEO Tony Giorgi put his capital behind sales channels and brands instead of mass-scale greenhouse investments.
Giorgi utilized a “capital-light model” – the opposite of his largest competitors.
It paid off.
After the dust settled, his competitors had lost billions of dollars and shuttered facilities in Canada and overseas, and Sensi says it became one of the only profitable cannabis producers in Canada.
Sensi, privately owned, opened its books to MJBizDaily to confirm last year’s profit but declined to release the specific amount.
“We do not issue products into the marketplace at negative margin. It’s part of our mantra. We’re not in business to lose money,” Giorgi said.
“We focused on innovating highly desirable brands, creating distribution channels and then working with LPs to get their craft products to market.
“We did not come out in 2019 with the intent of being the largest cultivator or extractor in the country.”
Sensi has a small cultivation facility and farm-gate store in St. Thomas, Ontario, and typically focuses on specialized strains.
The business also has a medical channel, called Sensi Medical, with approximately 4,000 active patients.
Positive cash flow notwithstanding, Sensi says the company, some 100 employees, stands out in a number of ways.
Management consumes cannabis daily (after workdays), and workers are invited to consume at monthly teembuilding meetings.
MJBizDaily spoke with Giorgi about his company and the outlook for the industry.
What did competitors, who destroyed millions of grams of cannabis and lost billions of dollars, get wrong in the years after legalization?
Between 2016 and 2019, you had a lot of companies with a flawed business model.
The entire business models were getting great genetics and growing great weed at scale.
Everyone was mass-scale.
They grew all that weed, and they all looked at each other and said, “Hey, do you want to buy it?”
Nobody focused on the distribution paths, and that’s how our business model is different.
What are other key details about your business model?
It’s a capital-light model focused on building channels. It’s not about focusing on growing commodity weed.
We built an ecosystem to rationalize quality weed versus undesirable weed but also to work with all the craft growers, who aren’t brand experts, in getting their product to market and underpinning our brands with that product.
We have five lines of business. We have a wholesale distribution line of business, where we’ve worked hard to sign supply agreements for spot buy, contract grow and joint ventures.
The wholesale distribution business is valuable to the company and the LPs that are part of the ecosystem, because it’s a distribution path for them.
The core line of business, which is our CPG brands business, is where we focus a lot of our efforts.
We invest a lot of money in the education, triaging and fulfillment of our medical patients through our fourth line of business, which is the medical marketplace (Sensi Medical).
We launched the medical marketplace last year with the intent of curating one of the best medical marketplaces in the country, by going to all the LPs and selecting all of their best medical products to have a one-stop shop.
As a patient of that clinic, why would I want to be committed to one LP when I could have all the best products in one marketplace? That was the vision behind the marketplace.
The farm-gate store is the fifth line of business.
Every line of business is capital-light and cash-flow positive.
You’re either the only standard licensed producer to turn an annual profit or you’re one of a small number. What are you doing differently?
We’re relentless about innovation, optimization and execution.
Those sound like fancy words, but the reality is this is my sixth startup company over the last 30 years.
We have one of the most experienced leadership teams.
We have a very disciplined approach to how we build companies.
We’re cannabis sommeliers by trade, so we’ve invested in learning everything about the plant.
We’re daily, experienced consumers, so we intimately have the academic and experiential knowledge to successfully navigate and launch highly desirable brands.
How do your employees factor into your success?
The one thing that I unequivocally would never lose sight of is the culture of the company and the employees.
We have gone above and beyond to create a culture and environment here that bleeds family and community.
We pay very competitive compensation, offer career growth and training and have a weekly 4/20 meeting, where the company shuts down at the end of the day and there’s a presentation in an educational component.
The staff is permitted to consume their cannabis of choice during that meeting. When the meeting is over, that transcends into a social time, or they wrap up for the day.
We’re trying to create an environment that’s transparent and promotes from within.
Culture and employees are the No. 1 priority for me and the management team.
You were involved in tech during the dot-com boom and bust, in your roles at Q9 Networks and others. What parallel, if any, do you see with cannabis, and how do you see it playing out?
There are a lot of parallels with the legalization of cannabis and the internet boom.
The years 1995 and 2000 in tech are very similar to 2015 to 2019 in cannabis.
By 2000, all the early e-commerce prospectors were a little premature, and therefore we had the big dot-com crash, which is effectively what we had in (cannabis) in 2021.
By 2003 and 2004, the real businesses – not the pump-and-dumps – the people building real cash-flow earning companies started to emerge.
We started seeing the likes of Amazon Web Services, Microsoft Azure, Google and Shopify emerge.
I kind of see the same parallel in cannabis.
I think the next three to five years will be very exciting for the cannabis space. The dust is settling.
The fly-by-nights are on their way out, and now, real companies are emerging that are building solid businesses and gaining market share on business fundamentals and profitable revenue.
I’m very optimistic that the next three to five years are going to be an exciting time in the cannabis space.
Source: https://mjbizdaily.com/sensi-brands-ceo-tony-giorigi-discusses-profits-canadian-cannabis-industry/
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Marijuana companies suing US attorney general in federal prohibition challenge
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business1 year ago
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year ago
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year ago
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year ago
Washington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year ago
Marijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year ago
Legal Marijuana Handed A Nothing Burger From NY State
-
Business1 year ago
Can Cannabis Help Seasonal Depression
-
Blogs1 year ago
Cannabis Art Is Flourishing On Etsy